Unicycive Therapeutics, Inc. Securities Fraud Class Action Opportunity

The Rosen Law Firm, which specializes in investor rights, has alerted buyers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) regarding a vital class action lawsuit. If you purchased Unicycive securities between March 29, 2024, and June 27, 2025, it’s crucial to be aware of important deadlines and options available to you.

Why You Should Act Now

The firm reminds investors that the deadline for assuming the role of lead plaintiff is on October 14, 2025. Taking this step may entitle you to compensation without having to pay any out-of-pocket fees or costs, thanks to a contingency fee arrangement that the firm offers.

Joining this class action could be pivotal for investors who find themselves adversely affected by the developments surrounding Unicycive. The lawsuit revolves around allegations of misleading statements and failures to disclose crucial information related to the FDA compliance concerning the company's manufacturing capabilities, as well as the regulatory prospects for their New Drug Application (NDA) related to oxylanthanum carbunate (OLC).

What Claims Are Being Made?

The heart of the lawsuit includes allegations that Unicycive’s management overstated their ability to meet FDA manufacturing standards and failed to disclose risks associated with the regulatory approval processes. When the actual situation was revealed, investors reportedly faced significant losses, triggering this legal action. As per the claims, these failures resulted in materially misleading public statements throughout the class period when shareholders were misled about the company's capabilities and future.

How to Participate

If you are interested in joining the Unicycive class action, you can find more information on the official submission page of the Rosen Law Firm at rosenlegal.com. Alternatively, you may contact Phillip Kim, an attorney at the firm, at 866-767-3653 or via email at [email protected] for further guidance.

It is essential to note that while you may join the class action, no class has been certified yet, meaning that as of now, you will not be represented unless you choose to retain counsel. The prospect of recovering any potential damages is independent of serving as the lead plaintiff, and investors have the choice to remain passive or take an active role in the proceedings.

Why Choose the Rosen Law Firm?

Choosing the right legal representation is crucial, especially in securities class actions. The Rosen Law Firm boasts a strong track record, having recovered substantial amounts for their clients, including notable settlements. They are recognized for their commitment to investor rights and have achieved ranking in the top tier for successful securities class action settlements. Laurence Rosen, a founding partner, has been honored as a leading figure in the plaintiffs’ bar by various legal publications.

Conclusion

If you purchased shares of Unicycive Therapeutics, Inc. within the specified class period, it’s in your best interest to act promptly to explore your rights as a potential member of this class action lawsuit. Engaging with experienced legal counsel like the Rosen Law Firm can significantly enhance your chances of receiving the compensation you may be owed due to the alleged securities fraud. Keep an eye on the unfolding developments of this case, and do not hesitate to take action by reaching out through their established channels on social media platforms like LinkedIn or Twitter.